

Michael J Townsend

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7295679/michael-j-townsend-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

51
papers

4,344
citations

31
h-index

53
g-index

53
ext. papers

5,184
ext. citations

11.5
avg, IF

4.95
L-index

#	Paper	IF	Citations
51	Antibodies against human endogenous retrovirus K102 envelope activate neutrophils in systemic lupus erythematosus. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	6
50	Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1835-1846	9.5	11
49	The kinase IRAK4 promotes endosomal TLR and immune complex signaling in B cells and plasmacytoid dendritic cells. <i>Science Signaling</i> , 2020 , 13,	8.8	11
48	Anti-vimentin antibodies: a unique antibody class associated with therapy-resistant lupus nephritis. <i>Lupus</i> , 2020 , 29, 569-577	2.6	6
47	Integration of eQTL and a Single-Cell Atlas in the Human Eye Identifies Causal Genes for Age-Related Macular Degeneration. <i>Cell Reports</i> , 2020 , 30, 1246-1259.e6	10.6	62
46	Response to: Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients by Buch. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e141	2.4	2
45	Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood. <i>Bioanalysis</i> , 2019 , 11, 1405-1418	2.1	28
44	Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes. <i>Cell Reports</i> , 2019 , 28, 2455-2470.e5	10.6	100
43	The Autoimmune Susceptibility Gene Regulates Macrophage-Mediated Resolution of Inflammation. <i>Journal of Immunology</i> , 2019 , 202, 1069-1078	5.3	8
42	Influence of genetic copy number variants of the human GLUT3 glucose transporter gene on protein expression, glycolysis and rheumatoid arthritis risk: A genetic replication study. <i>Molecular Genetics and Metabolism Reports</i> , 2019 , 19, 100470	1.8	2
41	IL-17A is associated with the breakdown of the blood-brain barrier in relapsing-remitting multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2019 , 332, 147-154	3.5	29
40	Activation of naïve CD4 T cells re-tunes STAT1 signaling to deliver unique cytokine responses in memory CD4 T cells. <i>Nature Immunology</i> , 2019 , 20, 458-470	19.1	16
39	Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 761-772	2.4	96
38	Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC). <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1642-1652	2.4	43
37	Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab. <i>Advances in Rheumatology</i> , 2019 , 59, 54	3	3
36	NF- κ B inducing kinase is a therapeutic target for systemic lupus erythematosus. <i>Nature Communications</i> , 2018 , 9, 179	17.4	58
35	The kinase TPL2 activates ERK and p38 signaling to promote neutrophilic inflammation. <i>Science Signaling</i> , 2017 , 10,	8.8	33

34	Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFN-driven lupus nephritis. <i>JCI Insight</i> , 2017 , 2, e90111	9.9	48
33	Reducing the risk of failure: biomarker-guided trial design. <i>Nature Reviews Drug Discovery</i> , 2016 , 15, 517-531	6.1	13
32	A Phase II study of the efficacy and safety of rontalizumab (rhuMab interferon- β) in patients with systemic lupus erythematosus (ROSE). <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 196-202	2.4	230
31	Fit-for-purpose biomarker immunoassay qualification and validation: three case studies. <i>Bioanalysis</i> , 2016 , 8, 2329-2340	2.1	6
30	Characterization of IL-17AA and IL-17FF in rheumatoid arthritis and multiple sclerosis. <i>Bioanalysis</i> , 2016 , 8, 2317-2327	2.1	21
29	Modular analysis of peripheral blood gene expression in rheumatoid arthritis captures reproducible gene expression changes in tumor necrosis factor responders. <i>Arthritis and Rheumatology</i> , 2015 , 67, 344-351	9.5	32
28	Stratified medicine in inflammatory disorders: From theory to practice. <i>Clinical Immunology</i> , 2015 , 161, 11-22	9	16
27	Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE. <i>Lupus Science and Medicine</i> , 2015 , 2, e000080	4.6	66
26	Ability of Interleukin-33- and Immune Complex-Triggered Activation of Human Mast Cells to Down-Regulate Monocyte-Mediated Immune Responses. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2343-53	9.5	39
25	Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation. <i>Nature</i> , 2015 , 528, 370-5	50.4	167
24	Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. <i>Arthritis Research and Therapy</i> , 2014 , 16, R90	5.7	211
23	Efficacy and safety of pateclizumab (anti-lymphotoxin- β) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study). <i>Arthritis Research and Therapy</i> , 2014 , 16, 467	5.7	32
22	Molecular and cellular heterogeneity in the Rheumatoid Arthritis synovium: clinical correlates of synovitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2014 , 28, 539-49	5.3	23
21	Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3666-76		139
20	Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1888-94	2.4	36
19	MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments. <i>Arthritis Research and Therapy</i> , 2011 , 13, R177	5.7	17
18	Association of endogenous anti-interferon- β autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2011 , 63, 2407-15		78
17	Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3681-91		48

16	A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis. <i>Science Translational Medicine</i> , 2011 , 3, 101ra92	17.5	60
15	B-cell targeted therapies in human autoimmune diseases: an updated perspective. <i>Immunological Reviews</i> , 2010 , 237, 264-83	11.3	179
14	Distal regions of the human IFNG locus direct cell type-specific expression. <i>Journal of Immunology</i> , 2010 , 185, 1492-501	5.3	27
13	Lymphotoxin-alpha-beta heterotrimers are cleaved by metalloproteinases and contribute to synovitis in rheumatoid arthritis. <i>Cytokine</i> , 2010 , 51, 78-86	4	36
12	Evaluation of heterophilic antibody blocking agents in reducing false positive interference in immunoassays for IL-17AA, IL-17FF, and IL-17AF. <i>Journal of Immunological Methods</i> , 2010 , 362, 70-81	2.5	29
11	The transcription factors T-bet and GATA-3 control alternative pathways of T-cell differentiation through a shared set of target genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 17876-81	11.5	161
10	Promising bone-related therapeutic targets for rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2009 , 5, 543-8	8.1	80
9	T-bet regulates metastasis rate in a murine model of primary prostate cancer. <i>Cancer Research</i> , 2004 , 64, 452-5	10.1	34
8	SIGN-R1 contributes to protection against lethal pneumococcal infection in mice. <i>Journal of Experimental Medicine</i> , 2004 , 200, 1383-93	16.6	122
7	Recent developments in the transcriptional regulation of cytolytic effector cells. <i>Nature Reviews Immunology</i> , 2004 , 4, 900-11	36.5	239
6	T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells. <i>Immunity</i> , 2004 , 20, 477-94	32.3	569
5	The absence of interleukin 9 does not affect the development of allergen-induced pulmonary inflammation nor airway hyperreactivity. <i>Journal of Experimental Medicine</i> , 2002 , 195, 51-7	16.6	118
4	IL-4 induces characteristic Th2 responses even in the combined absence of IL-5, IL-9, and IL-13. <i>Immunity</i> , 2002 , 17, 7-17	32.3	273
3	T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. <i>Journal of Experimental Medicine</i> , 2000 , 191, 1069-76	16.6	404
2	IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development. <i>Immunity</i> , 2000 , 13, 573-83	32.3	272
1	Antibody against envelope protein from human endogenous retrovirus activates neutrophils in systemic lupus erythematosus		2